2. Participants in included studies.
| Study name | Intervention(s) and comparator(s) | Screened/eligible (n) | Randomized (n) | Analyzed (n): efficacya | Analyzed (n): safetyb | Finishing trial (n (%)) |
| Gratzke 2017 | PUL | NR/91 | 45 | 37 | 45 | 44 (97.7) |
| TURP | 46 | 32 | 35 | 35 (76.0) | ||
| Total | 91 | 69 | 80 | 79 (86.8) | ||
| Roehrborn 2013 | PUL | 430/206 | 140 | 140 | 140 | 140 (100.0) |
| Sham | 66 | 66 | 66 | 66 (100.0) | ||
| Total | 206 | 206 | 206 | 206 (100.0) | ||
| Grand total | Intervention: PUL | — | 185 | 177 | 185 | 184 (99.4) |
| Comparator: sham | 66 | 66 | 66 | 66 (100.0) | ||
| Comparator: TURP | 46 | 32 | 35 | 35 (76.0) | ||
| Overall | 297 | 275 | 286 | 285 (95.9) | ||
n: number of participants; NR: not reported; PUL: prostatic urethral lift; TURP: transurethral resection of prostate. aThe number of participants analyzed for urological symptom scores. bThe number of participants with adverse events.